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Abstract: Although reducing blood pressure is the most important approach to reduce 
  cardiovascular outcomes in the hypertensive population, the majority of patients fail to attain 
the targets. Most patients with hypertension need at least 2 antihypertensive agents to achieve 
blood pressure goals. The 2007 European hypertension guidelines state that combined therapy 
is needed when monotherapy does not attain blood pressure objectives and as a first-line 
  treatment in high-risk patients. This point has been reinforced in the 2009 update of the European 
guidelines. The advantages of combination therapy are well documented with the potential for 
increased antihypertensive efficacy as a result of different mechanisms of action, and a lower 
incidence of adverse effects because of the lower doses used and the possible compensatory 
responses.   Moreover, the use of fixed dose combinations are specially recommended as they 
facilitate   treatment compliance. The inhibition of the renin-angiotensin system appears to be 
very beneficial in the treatment of patients with hypertension along the cardiovascular   continuum 
and the combination of a renin-angiotensin system inhibitor and a diuretic is particularly 
recommended. Many clinical trials have demonstrated the benefits of the fixed combination 
perindopril/  indapamide in the treatment of hypertension. The aim of this manuscript is to update 
the   published data on the efficacy and safety of this fixed combination.
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Introduction
Arterial hypertension, a major risk factor for the establishment and development of 
cerebrovascular, cardiovascular and renal diseases, is very prevalent worldwide. It has 
been estimated that about a quarter of the general population is hypertensive, a proportion 
that increases with age.1–3 In Spain, 44% of the middle-aged population and 68% of 
patients aged 60 years or older exhibit hypertension.1 In United States about 65 million 
people are hypertensive.2,3 It has been calculated that hypertension is responsible for 
1 of every 14 deaths for any reason and for 1 of every 2.5 cardiovascular deaths.4
Even small elevations above optimal systolic or diastolic blood pressure (BP) 
values increase the probability of cardiovascular outcomes.5 Thus, in 18,876 healthy 
subjects, an increased risk of new onset heart failure in individuals with systolic BP 
130–139 mmHg compared with those with optimal BP (,120 mmHg) has recently been 
reported, with a linear trend in heart failure risk across the normal range of   systolic BP.6 
Similar findings have been reported in patients with ischemic heart disease.7 A post hoc 
analysis of INVEST (International Verapamil SR-Trandolapril Study) trial, performed Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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in 22,576 patients with hypertension and coronary artery 
disease, showed there was a steep reduction in cardiovascu-
lar risk in parallel to the proportion of visits with controlled 
BP, independent of baseline characteristics and mean on-
treatment BP.7 In the classical systematic review of Collins 
et al8 a 42% stroke risk reduction (P , 0.0001) and a 14% 
coronary heart   disease risk reduction in those hypertensives 
who attained BP goals, when compared to those treated but 
not adequately controlled, was reported. As a result, it is 
crucial not only to reduce BP values but to achieve BP goals 
in order to improve cardiovascular prognosis.5
Although in the last decades BP control rates have 
  progressively improved (ie, in Spain, BP control has increased 
from ,20% in 1990s to the current 40%),9 they are far from 
optimal and this occurs everywhere (Italy about 31%, United 
  Kingdom 36%, Germany 40% and France 46%).2 However, 
after the results of EUROASPIRE III, it seems that this 
improvement has stopped or at least slowed.10 EUROASPIRE 
surveys analyzed rates of   modifiable   cardiovascular 
risk   factors in patients with coronary heart disease. 
EUROASPIRE I, II, and III were designed as   cross-sectional 
studies and included the same selected geographical areas and 
hospitals in the Czech Republic, Finland, France, Germany, 
Hungary, Italy, the   Netherlands, and Slovenia. These studies 
showed that although the proportion with raised total choles-
terol has   markedly decreased, from 94.5% in EUROASPIRE I 
to 76.7% in II, and 46.2% in III (P , 0.0001), the   proportion 
of patients with raised BP ($140/90 mmHg in patients 
  without   diabetes or $130/80 mmHg in patients with diabetes) 
remained unchanged (58.1% in EUROASPIRE I, 58.3% in II, 
and 60.9% in III; P = 0.49).10
These data suggest that, although in the general 
  hypertensive population BP control rates are rising, this does 
not occur in those hypertensive patients at higher risk such as 
those with coronary heart disease. In fact, as   cardiovascular 
risk increases, a lesser proportion of patients attain BP 
goals.10,11 This is very relevant, since nowadays the majority 
of patients attended by specialists or general practitioners, 
belong to high- or very high-risk groups.12,13 Furthermore, 
since the prevalence of diabetes, obesity and sedentary life 
style is growing, it is likely that the number of high risk 
hypertensive patients will rise in the future.14
Although it is well known that the majority of   hypertensive 
patients will need more than 1 antihypertensive drug to 
attain BP objectives (particularly those at higher risk),15,16 
several surveys have reported that combined therapy is 
  actually underused.9–12 The 2007 European guidelines for 
the   management of arterial hypertension, indicate that 
  combined therapy is required when monotherapy fails 
to attain BP goals. They also show that a combination of 
2 drugs at low doses as first line treatment, can be   prescribed 
when total   cardiovascular risk is high or very high, or 
when initial BP values are in the range of grade 2 or 3.5 
The   evidence that in the vast majority of hypertensives 
effective BP control can only be achieved by combination 
of at least 2   antihypertensive agents continues to grow, as 
a last update of European   guidelines shows. Moreover, 
the   combination of 2   antihypertensive drugs may offer 
  advantages also for treatment initiation, particularly in 
patients at high   cardiovascular risk in which early BP control 
may be   desirable.17 Fortunately, although the use of combined 
therapy is still low and far from optimal, its prescribing has 
improved in the last decade.18,19
The use of a combination of 2 antihypertensive agents 
at fixed doses in a single tablet should be preferred, since 
decreasing the number of pills that have to be taken daily 
has been associated with an improvement in compliance, 
and consequently, better BP control rates during   follow-up.20 
As current recommendations report, there are several 
2-drug fixed combinations suitable for clinical use.   However, 
trial evidence of outcome reduction has been obtained 
  particularly for the combination of a diuretic or a calcium 
channel blocker, with an angiotensin-converting enzyme 
(ACE) inhibitor, or a diuretic with an angiotensin receptor 
blocker. Importantly, the use of the angiotensin receptor 
blocker/calcium channel blocker combination also appears 
to be rational and effective.17 As a result, these combinations 
should be recommended for priority use. This manuscript 
aims to update the published data on the efficacy and safety 
of the fixed combination perindopril plus indapamide.
Renin-angiotensin system  
and organ damage
Although the renin-angiotensin aldosterone system (RAAS) 
is important for the cardiovascular system homeostasis, the 
BP control, and the sodium and water balance, its   excessive 
activation promotes the development and worsening of 
  cardiovascular disease.21 Angiotensin II is associated 
with all phases of cardiovascular disease, from the early 
(  hypertension), to the mid (left ventricular hypertrophy and 
microalbuminuria), to the late stages (myocardial infarction, 
heart failure stroke, and renal disease).
Left ventricular hypertrophy is one of the most   relevant 
  subclinical organ damage in patients with   hypertension.5 
Although many factors have been involved in the 
establishment and development of left ventricular   hypertrophy Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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in hypertension, it is likely that the RAAS activity and the 
increased afterload are the main ones.22 Its presence increases 
2- to 5-fold the risk of major cardiovascular events.23 However, 
left ventricular hypertrophy regression, or at least reduction, 
is associated with a better prognosis.5 Although the most 
  important point in the treatment of hypertensive   population 
with left ventricular hypertrophy is BP reduction, several trials 
have reported that RAAS inhibitors could be   recommended 
as first-line therapy in this setting.5,24,25
It is well known that renal disease and hypertension are 
closely related. Hypertension is one of the most frequent 
causes of new-onset renal disease and their progression 
toward end-stage renal failure and conversely, chronic 
  kidney disease promotes the development of   hypertension.26 
  Microalbuminuria is an early manifestation of renal 
  involvement in patients with hypertension, particularly in 
diabetic   population. The presence of microalbuminuria in this 
context has been related to an increase of mortality, and its 
reduction with a better prognosis.5 Many clinical trials have 
shown that RAAS inhibition is a very effective therapeutic 
strategy in   hypertensive patients with renal impairment.27,28 
RAAS   inhibition promotes a decrease of glomerular   pressure, 
a decline of albumin excretion rate due to the dilatation of 
efferent arterioles, and a reduction of local inflammation 
and growth in the glomerulus. This translates into a reduced 
  vascular trophic remodelling and results in different and 
  additive beneficial effects on renal function and structure.26
Endothelial dysfunction is a predictor of cardiovascular 
events in hypertensive patients.29,30 Endothelial dysfunction 
as well as vascular endothelial cell apoptosis occurs in the 
early atherosclerotic lesions, but also as cardiovascular disease 
progresses.31 This endothelial impairment damages the func-
tioning of endothelium, affecting nitric oxide bioavailability, 
promoting vasoconstriction, inflammation, thrombosis and 
platelet activation what finally provokes the development of 
atherosclerotic disease.32 By contrast, ACE inhibitors improve 
endothelium-dependent vasodilation in hypertensive patients, 
protecting them from ischemic heart disease.33
Pharmacology and rationale  
for the combination of perindopril  
and indapamide
Perindopril is a prodrug that is rapidly absorbed in the 
  gastrointestinal tract after oral administration.   Bioavailability 
of perindopril is 61%–85%. The biotransformation of 
  perindopril to perindoprilat, the active metabolite, is 
approximately 20%. Notably, food intake may reduce 
hepatic biotransformation to perindoprilat. The peak 
plasma concentration and the peak pharmacological activity 
of   perindoprilat occur at 3 to 4 hours and 4 to 6 hours, 
respectively, after oral administration of perindopril. The 
rates of protein   binding of perindoprilat are low (,30%). 
Free perindoprilat is   eliminated via the urine. Although the 
elimination half-life of the free fraction of perindoprilat is 
between 3 and 5 hours, the terminal half-life of the dissocia-
tion of perindoprilat from plasma and tissue ACE is about 25 
to 30 hours. The steady-state concentration of perindoprilat is 
reached within 4 days when chronically administered.34–36
Indapamide is an oral diuretic with natriuretic   properties 
that acts in the proximal segment of the distal tubule. 
  Interestingly, the main effect of indapamide is on sodium 
and chloride excretion, but with less effect on potassium 
or uric acid urine excretion. Nevertheless, there is an 
  appreciable increase in urinary volume only at doses greater 
than 2.5 mg/day. Despite these renal effects, it has been 
suggested that the reduction in vascular reactivity to pressor 
amines caused by indapamide has a more important role in 
its antihypertensive effect.34,37,38
Indapamide has high lipid solubility and as a consequence, 
its absorption from the gastrointestinal tract is fast 
(30 to 60 minutes after oral administration), and   complete. 
  Indapamide is bound to plasma proteins in 79% and 
has a   relatively low apparent volume of distribution of 
  approximately 60 L. Plasma elimination half life is biphasic 
and between 14 and 25 hours. The steady-state   concentration 
of indapamide is reached within 3 to 4 days when chronically 
administered. Indapamide is widely   metabolized in the Liver, 
principally by CYP2C9 and CYP3A4 isozymes, and by 
cytosolic hydrolysis enzymes. The main route of elimination 
is the urine, and 20 to 23% in the feces. In contrast to hydro-
chlorothiazide, indapamide does not adversely affect lipid 
profile or glucose tolerance either in hypertensive patients 
with diabetes.34,37,38
The combination of perindopril, an ACE inhibitor, 
and indapamide, a chlorosulphamoyl diuretic, is recom-
mended as one of the antihypertensive combinations of 
priority use by the last update of European hypertension 
guidelines.17 Due to their synergistic mechanisms of 
action, the doses at which this combination is given is up 
to 2 times lower than the usual dose used for monotherapy, 
showing a higher   antihypertensive effect with lesser side 
effects. On the one hand, as indapamide depletes the 
cell of sodium and of   calcium, this reduces the vascular 
response to angiotensin II and on the other hand, perin-
dopril blocks the activation of RAAS and sympathetic 
nervous system induced by   indapamide. Moreover, the Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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potassium depletion caused by indapamide is buffered by 
  perindopril due to its   potassium-sparing effect. Notably, the 
  co-administration of perindopril and indapamide does not 
change their   pharmacokinetic properties when   compared 
to both drugs in monotherapy, and this facilitates its 
administration.34,39
Efficacy and safety of the 
combination perindopril/
indapamide
Hypertension
Several randomized clinical trials and observational   studies 
have analyzed the benefits of the fixed combination perindo-
pril/indapamide in the treatment of   hypertensive population. 
In a study performed in stable   hypertensive patients with 
systolic BP .130 mmHg and/or diastolic BP . 85 mmHg, 
even with up to 2   antihypertensive drugs, excluding ACE 
inhibitors, angiotensin II receptor blockers or a diuretic, 
patients were   randomized to receive perindopril 2 mg/inda-
pamide 0.625 mg or   cilazapril 2.5 mg once daily for a period 
of 12 weeks after a 2-week placebo run-in phase.40 Although 
systolic BP was significantly reduced by both groups, dia-
stolic BP was significantly reduced only by the combination 
perindopril/indapamide. Notably, the response rate, defined 
as systolic BP # 140 mmHg and   diastolic BP # 90 mmHg 
at the last visit or a .20 mmHg reduction in systolic BP and/
or .10 mmHg reduction in diastolic BP, was significantly 
higher with the combination (100%) than with cilazapril 
(70%) (P = 0.0086). Interestingly, there was no difference in 
the number of adverse events between the 2 groups.
In the STRATHE trial, the efficacy and the tolerability 
of three different strategies in the treatment of   hypertension 
(low-dose combination, sequential monotherapy and 
  stepped-care) were compared.41,42 Hypertensive patients 
were randomized to a 9-month treatment. In the ‘low-dose 
combination’ group (n = 180), perindopril (2 mg) and 
indapamide (0.625 mg) were first administered with the 
possibility of increasing the doses in 2 steps up to 4 and 
1.25 mg respectively. In the ‘sequential monotherapy’ group 
(n = 176), the treatment was initiated with atenolol (50 mg), 
replaced if necessary by losartan (50 mg), and afterwards by 
amlodipine (5 mg). In the ‘stepped-care’ group (n = 177), 
valsartan, was given first at a 40 mg dose, then at a 80 mg 
dose, to be finally   co-administered with hydrochlorothiazide 
12.5 mg if required. The main results of this study showed 
that the proportion of patients that achieved BP goals, was 
significantly higher in the ‘low-dose combination’ group 
(62%) than in the ‘sequential monotherapy’ (49%, P = 0.02) 
and the ‘stepped-care’ group (47%, P = 0.005). Moreover, 
the percentage of patients that normalized their BP was 
  significantly greater in the ‘low-dose combination’ group 
(56%) than in the ‘sequential monotherapy’ (42%, P = 0.002) 
or in the ‘stepped-care’ group (42%, P = 0.004). Interestingly, 
these better BP results were not obtained at the expense of 
a worsening tolerability.
The Optimax II study was performed to assess whether 
the pre-existence of metabolic syndrome defined by the 
NCEP-ATP III criteria, had any impact on BP control in hyper-
tensive patients receiving a fixed perindopril/indapamide com-
bination therapy.43 A total of 24,069 hypertensive patients were 
prospectively included and the follow-up lasted 6 months. 
About 30% of patients exhibited metabolic syndrome. Patients 
were divided in 3 groups:   previously untreated, who received 
the combination therapy as initial treatment; previously treated 
but with unsatisfactory results and/or treatment intolerance, 
they had its previous treatment switched to perindopril/inda-
pamide; and previously treated, with good treatment toler-
ance but uncontrolled BP, who received the study treatment 
in adjunction to the previous one. The normalization rates 
were 70.3%, 68.4%, and 64.1%, respectively, (P , 0.0001). 
Interestingly, the pre-existence of metabolic syndrome did not 
show any significant influence on these figures.
A meta-analysis was performed to assess the   efficacy 
and safety profiles (through review of randomized, 
  controlled   trials) of the fixed, low-dose   combination 
  perindopril 2 mg and indapamide 0.625 mg given as 
first-line   antihypertensive therapy in patients with mild 
to   moderate hypertension.44 In this systematic review, a 
total of 11   trials (5,936 individuals) were reviewed. In the 
5   studies that   compared perindopril indapamide   versus 
  placebo, the   combination significantly reduced both systolic 
and diastolic BP values. In the other 6 studies,   perindopril 
indapamide was compared to other   antihypertensive 
therapies (  perindopril 4 mg/day in monotherapy, losartan 
50 mg/day, irbesartan 150 mg/day, enalapril 40 mg/day), 
showing significantly higher reductions in BP values with 
the combination   perindopril/indapamide. Adverse events 
and withdrawals were not significantly different between 
perindopril indapamide and control groups.
Although the results of controlled randomized   trials 
are very important, they are selective and significant 
  differences may remain between them and the ‘real world’ 
of general practice. Therefore, it is not always reliable 
to translate these results to clinical practice.45,46 In this 
  context,   observational studies may be useful to determine Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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the impact of compliance, tolerability and BP control in daily 
clinical activity.47,48 In a descriptive, multicenter survey carried 
out in primary care setting across Spain, general practitioners 
were asked about their own experience in the use of the fixed 
combination perindopril 2 mg plus indapamide 0.625 mg in 
  hypertensive patients for a minimum of 6 weeks.47 They found 
in 3,198 patients, that BP control rates increased from 1.1% at 
baseline, to 38.7% with the combination (Figure 1). Moreover, 
the great majority of physicians considered the efficacy and tol-
erability of the combination perindopril and indapamide as good 
or very good (88.8% and 96.2%,   respectively). Furthermore, 
most patients (92%) were   satisfied or very satisfied with the 
therapy. Another study with a similar design, but including spe-
cialists, was performed including a total of 5,126 patients with 
hypertension and diabetes.48 At baseline, 1.7% of the general 
practitioners’ patients and 1.3% of the specialists’ patients had 
their BP controlled, and with the combined therapy, BP control 
rates increased to 30.7% and 29.8%, respectively (P , 0.001 
vs baseline and not significantly different between groups) 
(Figure 1). Approximately 85% of physicians considered the 
efficacy and tolerability of combined therapy as ‘good’ or ‘very 
good’ and 93% of the patients were ‘satisfied’ or ‘very satisfied’ 
with the combined therapy.
Organ damage
The fixed combination perindopril/indapamide has been shown 
to be an effective therapy for the treatment of patients with 
hypertension and subclinical organ damage.49–52 In the PICXEL 
study,49 the efficacy of a strategy based on first-line combination 
with perindopril/indapamide versus monotherapy with enalapril 
in reducing echocardioghraphic left ventricular hypertrophy in 
hypertensive patients was compared. After 1 year, treatment 
systolic and diastolic BP decreased significantly more in the 
perindopril/indapamide than in the enalapril group (P , 0.0001 
and P = 0.003, respectively). Moreover, the left ventricular mass 
index decreased by 13.6 ± 23.9 g/m2 with perindopril/indap-
amide (P , 0.0001 vs baseline) and 3.9 ± 23.9 g/m2 with enal-
april (P , 0.005 vs baseline and P , 0.0001 between groups) 
(Figure 2). Both treatments were well tolerated. In an ancillary 
study of the PICXEL trial, the fixed combination perindopril/
indapamide reduced 24-hour and daytime systolic BP as well 
as pulse pressure significantly more than enalapril treatment 
(P , 0.01). No significant between-group differences were 
noted for diastolic BP or for night-time measurements. Trough/
peak ratios were higher with perindopril/indapamide than with 
enalapril. Moreover, more patients required dose increases with 
enalapril (87%) than with perindopril/indapamide (71%).50
The effects of the combination perindopril/indapamide 
on kidney disease have also been assessed.51 For this pur-
pose, the combination of perindopril/indapamide was 
  compared with enalapril monotherapy on albumin excretion 
rate (AER) in patients with type 2 diabetes, albuminuria, 
and hypertension in a 12-month, randomized study. After a 
4-week placebo period, patients with albuminuria .20 and 
,500 µg/min, were randomized to a combination of 2 mg 
perindopril/0.625 mg indapamide or to 10 mg daily enalapril. 
After a 12-week period, doses were adjusted on the basis of 
BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 
40 mg enalapril. Combined therapy exhibited higher systolic 
and diastolic BP reductions than enalapril (-3.0, P = 0.012 
and -1.5, P = 0.019, respectively) and higher AER reduction 
(-42% vs -27%, P = 0.002) (Figure 3). The greater AER 
reduction remained significant after adjustment for mean 
BP. Adverse events were similar in the 2 groups.
In a post hoc analysis of the ADVANCE (Action in Diabetes 
and Vascular Disease: Preterax and Diamicron MR Controlled 
Evaluation) trial, the effects of BP lowering and intensive glucose 
control on the incidence and progression of retinopathy in type 2 
diabetes patients were analyzed.52 The main results of this study 
showed that although BP lowering or intensive glucose control 
did not significantly reduce the incidence and progression of retin-
opathy, consistent trends towards a benefit were observed, with 
significant reductions in some lesions observed with both inter-
ventions. These effects of the 2 treatments were independent and   
additive.
Cardiovascular events
Several and important trials have specifically studied the 
efficacy of the combination perindopril/indapamide on cardio-
vascular events.53–63 The PROGRESS (perindopril protection 
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against recurrent stroke study) trial, was designed to determine 
the effects of a BP-lowering regimen in hypertensive and 
non-hypertensive patients with a history of stroke or transient 
ischemic attack.54–56 A total of 6,105 subjects from 172 centers 
in Asia, Australasia, and Europe were randomized to active 
treatment consisting of a flexible regimen based on perindopril 
(4 mg daily), with the addition of indapamide at the discre-
tion of treating physicians (n = 3051) or placebo (n = 3054). 
The primary end point of the study was total stroke (fatal or 
non-fatal). After a 4-year follow-up, perindopril/indapamide 
reduced BP by 9/4 mmHg. Those treated with perindopril/inda-
pamide exhibited a 28% relative risk reduction (95% CI 17–38, 
P , 0.0001) in the primary outcome, and a 26% risk reduction 
for total major vascular events. There were similar reductions 
in the risk of stroke in hypertensive and non-hypertensive 
subgroups (all P , 0.01). The combination perindopril/inda-
pamide reduced BP by 12/5 mmHg and stroke risk by 43%, 
whereas perindopril in monotherapy reduced BP by 5/3 mmHg, 
without a discernable reduction in the risk of stroke.
In the ADVANCE trial,57–61 the effects of the routine admin-
istration of the combination perindopril/indapamide on serious 
vascular events in patients with diabetes, irrespective of initial 
BP levels or the use of other BP-lowering drugs were assessed. 
After a 6-week active run-in period, 11,140 patients with type 
2 diabetes were randomized to the combination perindopril/
indapamide or placebo, in addition to current therapy. The 
primary endpoints were a composite of major macrovascular 
and microvascular events, defined as death from cardiovascular 
disease, non-fatal stroke or non-fatal myocardial infarction, 
and new or worsening renal or diabetic eye disease. After a 
mean of 4.3 years of follow-up, those assigned to perindopril/
indapamide had a mean reduction in systolic BP of 5.6 mmHg 
and diastolic BP of 2.2 mmHg. The relative risk of a major 
macrovascular or microvascular event was reduced by 9% 
(P = 0.04). The relative risk of death from cardiovascular 
disease was reduced by 18% (P = 0.03) and death from any 
cause by 14% (P = 0.03) (Table 1). The fixed combination of 
perindopril and indapamide was well tolerated. The authors 
concluded that the results of the ADVANCE trial suggest that 
over 5 years, 1 death of any cause would be averted among 
every 79 patients assigned to active therapy.
A recent combined analysis using individual data from 
ADVANCE, EUROPA, and PROGRESS studies was per-
formed to determine the consistency of the treatment effect of 
a perindopril-based regimen in patients with vascular disease 
or at high risk of vascular disease.62 All-cause mortality and 
major cardiovascular outcomes during a follow-up of about 
4 years in 29,463 patients randomly assigned to a perindopril-
based treatment regimen or placebo were analyzed. The 
perindopril-based regimens were associated with a signifi-
cant reduction in all-cause mortality (HR 0.89; P = 0.006), 
cardiovascular mortality (HR 0.85; P = 0.004), non-fatal 
myocardial infarction (HR 0.80; P , 0.001), stroke (HR 0.82; 
P = 0.002), and heart failure (HR 0.84; P = 0.015).
The results of the HYVET (Hypertension in the Very 
Elderly Trial) study have been very important to clarify 
how the management of the hypertensive population aged 
80 years or older should be.63 In this study, 3,845 patients 
from Europe, China, Australasia, and Tunisia, who were 
$80 years and had a sustained systolic BP $ 160 mmHg, 
were randomized to receive either indapamide (sustained 
release, 1.5 mg) or matching placebo. Perindopril (2 or 4 mg), 
or matching placebo, was added if necessary to achieve the 
target BP of 150/80 mmHg. The primary end point was 
fatal or nonfatal stroke. After 2 years of treatment, mean 
BP was 15.0/6.1 mmHg lower in the active-treatment group 
than in the placebo group. Active treatment was associated 
with a 30% reduction in the rate of fatal or nonfatal stroke 
(P = 0.06), a 39% reduction in the rate of death from stroke 
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(P = 0.05), a 21% reduction in the rate of death from any 
cause (P = 0.02), a 23% reduction in the rate of death from 
cardiovascular causes (P = 0.06), and a 64% reduction in the 
rate of heart failure (P , 0.001) (Table 2).
Safety and tolerability
The fixed combination perindopril plus indapamide is a safe 
and well-tolerated drug, with a low incidence of adverse 
events. In general, drug-related adverse events are mild 
and transient with a very low discontinuation rate (about 
2%). The most frequent adverse events reported with the 
fixed combination perindopril (2–4 mg) plus indapamide 
(0.625–1.25 mg) are cough (4.4%), headache (3.1%), 
  asthenia (1.6%), dizziness (1.4%) and flu-like symptoms 
(1.2%). Due to their complementary mechanisms of action, 
hyponatremia and hypokalemia are uncommon with perindo-
pril/indapamide therapy. This antihypertensive c  ombination 
does not adversely affect lipid profile or glucose tolerance 
even in hypertensive patients at risk.34
The combination perindopril and indapamide is 
  contraindicated in patients with a history of   previous 
  hypersensitivity to either of the active compounds, 
  perindopril or indapamide, in subjects with bilateral renal 
artery stenosis (or unilateral in subjects with only one 
  kidney), in patients with severe renal insufficiency (creati-
nine clearance below 30 mL/min), as well as during preg-
nancy and for lactating women.34 It should be noted that these 
  contraindications are the same for all RAAS blockers.
Conclusions and place in therapy
The majority of patients with hypertension often require 
more than one drug to achieve BP goals. The last update 
of the European guidelines for the management of arterial 
hypertension recommends the use of fixed combinations in 
those patients that require more than one antihypertensive 
drug to attain BP objectives. The combination of an ACE 
inhibitor with a diuretic is highly recommended in this con-
text. Many trials have demonstrated the beneficial effects 
of perindopril on the whole spectrum of the cardiovascular 
continuum.
Clinical trials have shown that perindopril/indapamide is 
an effective and well-tolerated fixed-dose antihypertensive 
combination. As expected, it provides greater   antihypertensive 
efficacy than either component taken as monotherapy. This 
combination has been demonstrated to reduce left ventricu-
lar mass index as well as albumin excretion rate, probably 
beyond its antihypertensive effect. But, moreover, relevant 
controlled randomized clinical trials such as ADVANCE, 
PROGRESS or HYVET have importantly shown that treat-
ment with perindopril/indapamide reduces cardiovascular 
outcomes in different contexts, such as the diabetic popula-
tion, a history of cerebrovascular disease or the elderly.
The ACCOMPLISH trial showed that not all antihyper-
tensive fixed combinations have the same impact on cardio-
vascular outcomes. In this trial, the benazepril–amlodipine 
combination was superior to benazepril–  hydrochlorothiazide 
in reducing cardiovascular events in a hypertensive popula-
tion with a high proportion of patients with diabetes and 
obesity.64 It should be kept in mind that in this situation, 
a thiazide may worsen glucose and lipid profiles and this 
could influence outcomes. However, indapamide does not 
have these deleterious effects on lipid and glucose profiles. 
Although both indapamide and thiazides are diuretics, 
their mechanisms of action differ, as well as their clinical 
benefits on vascular protection. Moreover, the evidence on 
the benefits of perindopril in outcome trials is much more 
Table 1 Main results of ADvANCE trial57
Variables Relative risk reduction Hazard ratio (95% CI) P
Major macrovascular or microvascular event 9% 0.91 (0.83–1.00) 0.041
Death from cardiovascular disease 18% 0.82 (0.68–0.98) 0.027
Death from any cause 14% 0.86 (0.75–0.98) 0.025
Abbreviation: CI, confidence interval.
Table 2 Main results of HYvET trial63
Variables Relative risk reduction 95% confidence interval P
Fatal or nonfatal stroke 30% -1 to 51 0.06
Death from stroke 39% 1 to 62 0.05
Death from any cause 21% 4 to 35 0.02
Death from cardiovascular causes 23% -1 to 40 0.06
Rate of heart failure 64% 42 to 78 ,0.001Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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robust than that with benazepril. As a result, the results of 
ACCOMPLISH should not be directly applied to the fixed 
combination perindopril-indapamide.
As a result, as 2007 ESH/ESC guidelines recommend, 
the fixed combination perindopril/indapamide at low doses 
could be suitable in the treatment of hypertensive patients at 
high or very high risk, as initial therapy.
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